# SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

> **NCT05552807** · PHASE1 · UNKNOWN · sponsor: **Sinocelltech Ltd.** · enrollment: 120 (estimated)

## Conditions studied

- Head and Neck Squamous Carcinoma

## Interventions

- **DRUG:** SCT-I10A
- **DRUG:** SCT200
- **DRUG:** paclitaxel
- **DRUG:** docetaxel

## Key facts

- **NCT ID:** NCT05552807
- **Lead sponsor:** Sinocelltech Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-06-15
- **Primary completion:** 2023-09
- **Final completion:** 2023-09
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2022-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05552807

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05552807, "SCT200 in Combination With SCT-I10A/Paclitaxel/Docetaxel in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05552807. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*